Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S-[+]-Apomorphine - Aclipse Therapeutics

Next Previous
Drug Profile

S-[+]-Apomorphine - Aclipse Therapeutics

Alternative Names: Apomorphine - Aclipse Therapeutics; M 102

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Sheffield
  • Developer Aclipse Therapeutics; University of Sheffield
  • Class Analgesics; Antiparkinsonians; Aporphines; Catechols; Erectile dysfunction therapies; Neuroprotectants; Phenanthrenes; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Heat shock transcription factor stimulants; NF-E2-related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Friedreich's ataxia; Parkinson's disease
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in United Kingdom (PO)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (PO)
  • 10 Oct 2023 Preclinical trials in Friedreich's ataxia in USA, United Kingdom (PO), prior to October 2023 (Aclipse Therapeutics pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top